{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-126758","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2024-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.442371+00:00","generated_at":"2026-05-29T05:27:31.559187+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rigel reports initial Phase 1b data for R289 in LR-MDS; 40% response rate in evaluable TD patients at ≥500 mg QD","bullets":["22 LR-MDS patients enrolled; median age 76, median 3 prior therapies; 73% high transfusion burden.","R289 well tolerated; most common AEs diarrhea/fatigue (27%), chills/nausea/pruritus (23%), all Grade 1/2.","Among evaluable TD patients at doses ≥500 mg QD, 40% (4/10) achieved RBC-TI/HI-E; 3 achieved RBC-TI ≥8 weeks.","Two HTB patients achieved RBC-TI >24 weeks; median RBC-TI duration 29 weeks (range 12.7-51.9 weeks).","FDA granted Fast Track designation for R289 in previously-treated transfusion-dependent LR-MDS."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-126758","json":"https://secwatch.observer/filing/0001104659-24-126758.json","markdown":"https://secwatch.observer/filing/0001104659-24-126758.md","text":"https://secwatch.observer/filing/0001104659-24-126758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924126758/0001104659-24-126758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465924126758/tm2430504d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T05:27:31.559187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}